Bicara Therapeutics
Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. The company's lead program, ficerafusp alfa, is a bifunctional antibody combining an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β). Through dual-targeting mechanism, ficerafusp alfa has potential to exert potent anti-tumor activity by simultaneously blocking cancer cell-intrinsic EGFR survival and proliferation, as well as immunosuppressive TGF-β signaling within the tumor microenvironment. Lead indication is head and neck squamous cell carcinoma (HNSCC).
Public Company
Bicara Therapeutics is publicly traded
IPO'd on September 13, 2024
This company is no longer available on our private secondary market. Shares can be traded publicly under BCAX.
Overview
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2018
Total Funding
$675M
3 rounds
Funding
Total raised $675M across 3 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
Series C
Date
December 12, 2023
Amount
$165M
Valuation
—
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| December 12, 2023 | Series C | $165M | — | Braidwell LP, TPG |
| March 6, 2023 | Series B | $108M | — | Red Tree Venture Capital, RA Capital Management |
| March 15, 2021 | Seed/Series A | $40M | — | Biocon Biologics |
Prominent Investors
Leadership
Claire Mazumdar
Chief Executive Officer
David Raben
Chief Medical Officer
Bicara Therapeutics Investment FAQ
Bicara Therapeutics FAQ
Yes, Bicara Therapeutics is publicly traded under the ticker symbol BCAX on the NASDAQ. The company went public in September 13, 2024.
Bicara Therapeutics trades under the ticker symbol BCAX on the NASDAQ. It began trading in September 13, 2024.
Bicara Therapeutics (BCAX on the NASDAQ) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker BCAX to place an order.
Bicara Therapeutics went public in September 13, 2024 via ipo. Bicara Therapeutics completed initial public offering on NASDAQ on September 13, 2024 under ticker BCAX. Company priced 20.125 million shares at $18.00 per share, raising gross proceeds of approximately $362 million. IPO closed September 16, 2024. Offering was co-managed by Morgan Stanley, TD Cowen, Cantor, and Stifel.
Bicara Therapeutics raised $675M across 3 disclosed funding rounds prior to its public listing.
Bicara Therapeutics is headquartered in Boston, MA.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.